Latest Trustworthy News from Dr. Mercola - delivered straight to your inbox!

Ivermectin vs. Merck's New Antiviral, Molnupiravir

Analysis by Dr. Joseph Mercola Fact Checked

Story at-a-glance

  • One paper compared Merck's data on molnupiravir against peer-reviewed data on ivermectin and found ivermectin has a low side effect profile, costs less than molnupiravir and is more effective against SARS-CoV-2


By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Service.